742P - Investigation of a functional polymorphism in the epidermal growth factor gene for pathogenesis and prognosis of hepatocellular carcinoma in Japanes...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Hepatobiliary Cancers
Presenter Masaya Suenaga
Authors M. Suenaga1, S. Yamada2, T. Fujii3, B.C. Fuchs4, N. Okumura2, G. Nakayama5, S. Takeda2, K.K. Tanabe4, Y. Kodera6
  • 1Gastroenterological Surgery (surgery Ii) Dept., Nagoya University Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 2Department Of Gastroenterological Surgery (surgery Ii), Nagoya University Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 3Department Of Surgery Ii, Nagoya University, 466-8550 - Nagoya/JP
  • 4Division Of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston/US
  • 5Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 6Department Of Surgery Ii, Nagoya University Graduate School of Medicine, 466-8550 - Nagoya/JP



A single nucleotide polymorphism (SNP) in the epidermal growth factor (EGF) has been investigated as a predictor of hepatocellular carcinoma (HCC). Previous reports demonstrated that an A to G transition at position 61 in the 5′ untranslated region of the EGF gene was identified, and that G/G genotype was associated with an increased risk of developing HCC compared with the A/G and A/A genotype. It has been reported that there are differences in the distribution of polymorphisms by race, there is no report in the Japanese population.


To examine the relationship between EGF gene polymorphism genotype and the development and prognosis of HCC in the Japanese population.


Restriction fragment-length polymorphism was used to determine the EGF gene polymorphism genotype in two hundred and thirteen patients with HCC, who underwent resection in our department between 1996 and 2010. The correlation between these values and clinicopathological factors and prognosis were statistically analyzed. 2) The level of EGF mRNA expression in cancerous tissues was measured by quantitative reverse transcription-PCR. 3) EGF SNP was also analyzed in one hundred and forty patients with hepatitis and liver cirrhosis.


1) A/A, A/G, and G/G genotype were 5.2%, 43.7%, and 51.2% in the Japanese patients with HCC. A/A patients had better overall and disease-free prognosis than other genotypes, although no significant differences were found. 2) EGF mRNA expression in G/G patients was significantly higher than that in A/A patients (P = 0.04). 3) A/A, A/G, and G/G genotype were 7.1%, 34.3%, and 58.6% in patients without HCC. Analysis of the distribution of allelic frequencies revealed that odds ratio of developing HCC was 1.76 (95% CI 0.69-4.47, P = 0.23) in A/G patients, and 1.21 (95% CI 0.48-3.00, P = 0.68) in G/G patients, compared with A/A patients.


EGF 61*G allele was associated with greater transcript stability and EGF expression in the Japanese population. The EGF gene polymorphism genotype was associated with risk for development of HCC.


All authors have declared no conflicts of interest.